Drug intelligence / Profile preview

Xynase

Development stage: Unknown
Lead developer: Profounda
Modality: Device-based Delivery → Drug Delivery Systems
Administration: Intranasal

Overview

Xynase is an over-the-counter, drug-free saline nasal spray formulated with xylitol. Developed and marketed by Profounda, it is designed to moisturize the nasal passages and provide relief from dryness, congestion, and sinus pressure associated with allergies, nosebleeds (epistaxis), and environmental factors. The inclusion of xylitol helps to repel bacteria and enhance the moisturizing effects of the saline solution, offering a safe alternative to steroid-based nasal sprays for both adults and children. It is administered intranasally and is composed of natural ingredients, ensuring a side-effect-free experience.

Brand names: Xynase
Other names: Xynase Nasal Spray

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Xynase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xynase.

Explore the full profile